Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 23;14(6):538.
doi: 10.3390/antibiotics14060538.

Efficacy of Endolysin LysAB1245 Combined with Colistin as Adjunctive Therapy Against Colistin-Resistant Gram-Negative Bacteria

Rosesathorn Soontarach  1   2   3 , Supayang Piyawan Voravuthikunchai  1 , Potjanee Srimanote  4 , Sarunyou Chusri  2
Affiliations

Efficacy of Endolysin LysAB1245 Combined with Colistin as Adjunctive Therapy Against Colistin-Resistant Gram-Negative Bacteria

Rosesathorn Soontarach et al. Antibiotics (Basel). .

Abstract

Background: Colistin resistance among Gram-negative nosocomial pathogens is an increasing concern. The bacteriophage-encoded lytic enzyme endolysin LysAB1245, which targets bacterial peptidoglycan, was evaluated as a potential antibacterial agent in combination with colistin as a therapeutic approach. Methods: Clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa, along with two reference strains, were used to assess the antibacterial activity of LysAB1245 and colistin, individually and in combination. Antibacterial susceptibility was assessed by broth microdilution. Synergistic interactions were determined using checkerboard assays and confirmed by time-kill kinetics. Resistance development was assessed after several rounds of exposure to each agent, either alone or in combination. Results: In this study, the synergistic activity of the LysAB1245/colistin combination therapy was found in some clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa, resulting in a reduction in the MICs of both LysAB1245 and colistin. The bactericidal effects, with a significant, more than 3-log reduction in CFU/mL (p < 0.01), were observed in representative synergistic isolates within 4 h of treatment with the combination of LysAB1245 at 1/4 × MIC and colistin at 1/4 × MIC. Scanning electron microscope micrographs confirmed bacterial cell damage upon treatment with the combination. Additionally, treatment with LysAB1245 in combination with colistin had no effect on the development of bacterial resistance after multiple passages. Conclusions: Combining LysAB1245 with a last-resort antibiotic like polymyxins (colistin) could be used as a promising new antibacterial strategy for preventing and controlling antibiotic-resistant Gram-negative bacteria.

Keywords: antibacterial agent; antibiotic-resistant bacteria; colistin; combination; endolysin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Time-kill curve of Acinetobacter baumannii AB01 isolate after treatment with colistin and endolysin LysAB1245, both individually and in combination, for 18 h. Results obtained from two independent experiments performed in triplicate are expressed as mean ± standard deviation (SD). Statistical analysis was compared with the combination, ** p < 0.01, and NS means non-significant.
Figure 2
Figure 2
Time-kill curve of Pseudomonas aeruginosa PA04 isolate after treatment with colistin and endolysin LysAB1245, both individually and in combination, for 18 h. Results obtained from two independent experiments performed in triplicate are expressed as mean ± standard deviation (SD). Statistical analysis was compared with the combination, ** p < 0.01, and NS means non-significant.
Figure 3
Figure 3
Scanning electron micrographs of Acinetobacter baumannii AB01 after exposure to LysAB1245 at 1/4 × MIC combined with colistin at 1/4 × MIC (A), LysAB1245 at 1/4 × MIC (B), colistin at 1/4 × MIC (C), and the control (D), all shown at a magnification of 5000×.
Figure 4
Figure 4
Scanning electron micrographs of Acinetobacter baumannii AB01 after exposure to LysAB1245 at 1/4 × MIC combined with colistin at 1/4 × MIC (A), LysAB1245 at 1/4 × MIC (B), colistin at 1/4 × MIC (C), and the control (D), all shown at a magnification of 20,000×.
Figure 5
Figure 5
Scanning electron micrographs of Acinetobacter baumannii AB01 after exposure to LysAB1245 at 1/4 × MIC combined with colistin at 1/4 × MIC (A), LysAB1245 at 1/4 × MIC (B), colistin at 1/4 × MIC (C), and the control (D), all shown at a magnification of 40,000×. The presence of cell membrane damage is indicated by a circle symbol.
Figure 6
Figure 6
Scanning electron micrographs of Pseudomonas aeruginosa PA04 after exposure to LysAB1245 at 1/4 × MIC combined with colistin at 1/4 × MIC (A), LysAB1245 at 1/4 × MIC (B), colistin at 1/4 × MIC (C), and the control (D), all shown at a magnification of 5000×.
Figure 7
Figure 7
Scanning electron micrographs of Pseudomonas aeruginosa PA04 after exposure to LysAB1245 at 1/4 × MIC combined with colistin at 1/4 × MIC (A), LysAB1245 at 1/4 × MIC (B), colistin at 1/4 × MIC (C), and the control (D), all shown at a magnification of 20,000×.
Figure 8
Figure 8
Scanning electron micrographs of Pseudomonas aeruginosa PA04 after exposure to LysAB1245 at 1/4 × MIC combined with colistin at 1/4 × MIC (A), LysAB1245 at 1/4 × MIC (B), colistin at 1/4 × MIC (C), and the control (D), all shown at a magnification of 40,000×. The presence of cell membrane damage is indicated by a circle symbol.
See this image and copyright information in PMC

References

    1. Lepape A., Jean A., De Waele J., Friggeri A., Savey A., Vanhems P., Gustin M.P., Monnet D.L., Garnacho-Montero J., Kohlenberg A. European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria. Antimicrob. Resist. Infect. Control. 2020;9:1. doi: 10.1186/s13756-019-0662-8. - DOI - PMC - PubMed
    1. Sader H.S., Mendes R.E., Streit J.M., Carvalhaes C.G., Castanheira M. Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018–2020) Diagn. Microbiol. Infect. Dis. 2022;102:115557. doi: 10.1016/j.diagmicrobio.2021.115557. - DOI - PubMed
    1. Salam M.T., Bari K.B., Rahman M.M., Gafur D.M.M., Faruk M.O., Akter K., Irin F., Ashakin M.R., Shaikat T.A., Das A.C., et al. Emergence of antibiotic-resistant infections in ICU patients. J. Angiother. 2024;8:1–9.
    1. Edwardson S., Cairns C. Nosocomial infections in the ICU. Anaesth. Intensive Care Med. 2019;20:14–18. doi: 10.1016/j.mpaic.2018.11.004. - DOI
    1. Lakbar I., Medam S., Ronflé R., Cassir N., Delamarre L., Hammad E., Lopez A., Lepape A., Machut A., Boucekine M., et al. Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia. Sci. Rep. 2021;11:16497. doi: 10.1038/s41598-021-95852-4. - DOI - PMC - PubMed

LinkOut - more resources